Nebivolol Orion (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Orion, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and may be used in heart failure management in appropriate patients.

GNH USA supplies Nebivolol Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for conditions within the cardiovascular disease pathway, primarily hypertension and related disorders.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Heart failure: improves cardiac output and symptoms in patients with reduced ejection fraction. Cardiovascular risk reduction: contributes to lower incidence of stroke and myocardial infarction in treated individuals.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nasal congestion or runny nose. - Gastrointestinal discomfort such as nausea. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Acute heart failure decompensation. - Bronchospasm in patients with reactive airway disease. - Allergic reactions: rash, itching, or swelling.

Before initiating nebivolol therapy, consider patient‑specific factors and monitor appropriately.

Cardiovascular assessment: evaluate baseline blood pressure and heart rate. Renal or hepatic impairment: adjust monitoring as clearance may be affected. Concomitant β‑blockers: avoid duplicate therapy to prevent excessive β‑blockade. Pregnancy and lactation: use only if potential benefit justifies potential risk. Drug‑specific warnings: discontinue if severe bradycardia or hypotension occurs. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of additive hypotension. - Calcium channel blockers (e.g., verapamil, diltiazem): can enhance bradycardic effects.

Moderate Interactions (Monitor Closely): - Non‑selective β‑blockers: monitor heart rate and blood pressure. - Antidiabetic agents: nebivolol may mask hypoglycemia symptoms. - NSAIDs: may reduce antihypertensive efficacy.